IL6 and inflammatory bowel disease: Anti-TNF-α agents not only reduce the expression of proinflammatory cytokines (such as IL-6, IL-12a, IL-17A and TNF) in the intestinal mucosa of IBD, but also alter the release of antimicrobial peptides by the intestinal flora.